FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098486516> ?p ?o ?g. }

• W2098486516 endingPage "1199" @default.
• W2098486516 startingPage "1190" @default.
• W2098486516 abstract "What’s known on the subject? and What does the study add? • Six targeted agents – sorafenib, sunitinib, pazopanib, bevacizumab, temsirolimus and everolimus – have been approved for the treatment of advanced renal cell carcinoma (RCC) based on evidence from large randomized controlled trials (RCTs). However, no head‐to‐head trials have been conducted to evaluate the relative efficacy of these agents in this setting. • Patient populations included in clinical trials do not accurately reflect the wider population of patients with RCC, as certain subgroups, such as the elderly or those with co‐morbidities, are typically under‐represented. • The optimum choice of therapy should be based on patient characteristics, nature of disease, and history and aims of therapy; however, there is currently no clear guidance for physicians in this decision‐making process. • A patient‐focussed schema has been developed that acknowledges nine different patient‐, disease‐, and treatment‐related factors relevant to clinical decision‐making, and provides a visual indication of the strength of evidence with which a particular agent can be recommended for use in specific subgroups. • To demonstrate the applicability of this tool, a review of all available evidence (published articles, congress presentations and personal communications) for sorafenib in RCC was conducted by a panel of experts, findings from which showed that sorafenib can be recommended for use in various subgroups of differing age, prognosis, performance status, tumour burden and distribution, treatment history and co‐morbidity. • This patient‐focussed approach has broad application and can be used to assess other agents and tumour types. Randomized controlled trials (RCTs) show that six targeted agents – sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab and pazopanib – improve outcome in advanced renal cell carcinoma (RCC). The populations enrolled in the pivotal phase III studies differed, and, to date, no head‐to‐head comparisons allow us to judge relative efficacy and tolerability. Populations recruited to RCTs under‐represent certain patient subtypes, notably the elderly and those with comorbidities. Choosing the agent most appropriate in a specific case requires that we take into account the characteristics of the patient, the nature of their disease, and the history and aims of therapy. Data from expanded access programmes and clinical experience may be as relevant as the results of RCTs when making this difficult decision. To show how different sources of data can be integrated, we propose a schema that acknowledges nine patient‐, disease‐, and treatment‐related factors relevant to clinical decision‐making and provides an easily understood visual indication of the strength with which a particular agent can be recommended for use in specific subgroups of patients. As an example, we show how this tool shows the suitability of sorafenib in RCC subpopulations of differing age, prognosis, performance status, tumour burden and distribution, treatment history, and comorbidity. This patient‐focused approach has broad application to other agents and tumour types." @default.
• W2098486516 created "2016-06-24" @default.
• W2098486516 creator A5033091020 @default.
• W2098486516 creator A5049048398 @default.
• W2098486516 creator A5062519984 @default.
• W2098486516 creator A5074756323 @default.
• W2098486516 creator A5090509109 @default.
• W2098486516 date "2010-11-15" @default.
• W2098486516 modified "2023-10-18" @default.
• W2098486516 title "A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options" @default.
• W2098486516 cites W1520255941 @default.
• W2098486516 cites W1967884480 @default.
• W2098486516 cites W1970351257 @default.
• W2098486516 cites W1970600886 @default.
• W2098486516 cites W1971358860 @default.
• W2098486516 cites W1973003011 @default.
• W2098486516 cites W1974166228 @default.
• W2098486516 cites W1978440799 @default.
• W2098486516 cites W1978670159 @default.
• W2098486516 cites W1985309655 @default.
• W2098486516 cites W1988935694 @default.
• W2098486516 cites W1999966467 @default.
• W2098486516 cites W2022170158 @default.
• W2098486516 cites W2032349891 @default.
• W2098486516 cites W2032400400 @default.
• W2098486516 cites W2040339694 @default.
• W2098486516 cites W2040527839 @default.
• W2098486516 cites W2048169189 @default.
• W2098486516 cites W2074192749 @default.
• W2098486516 cites W2078449820 @default.
• W2098486516 cites W2091703907 @default.
• W2098486516 cites W2092100683 @default.
• W2098486516 cites W2096057999 @default.
• W2098486516 cites W2098136315 @default.
• W2098486516 cites W2099199992 @default.
• W2098486516 cites W2099259685 @default.
• W2098486516 cites W2099752220 @default.
• W2098486516 cites W2100669312 @default.
• W2098486516 cites W2104835206 @default.
• W2098486516 cites W2106453307 @default.
• W2098486516 cites W2110720470 @default.
• W2098486516 cites W2116177733 @default.
• W2098486516 cites W2118677643 @default.
• W2098486516 cites W2125921322 @default.
• W2098486516 cites W2131444088 @default.
• W2098486516 cites W2134280436 @default.
• W2098486516 cites W2137822543 @default.
• W2098486516 cites W2143782771 @default.
• W2098486516 cites W2143813821 @default.
• W2098486516 cites W2145011189 @default.
• W2098486516 cites W2147186814 @default.
• W2098486516 cites W2149456801 @default.
• W2098486516 cites W2153867442 @default.
• W2098486516 cites W2155012968 @default.
• W2098486516 cites W2156871508 @default.
• W2098486516 cites W2157262448 @default.
• W2098486516 cites W2161558746 @default.
• W2098486516 cites W2161797239 @default.
• W2098486516 cites W2162225483 @default.
• W2098486516 cites W2162424705 @default.
• W2098486516 cites W2166271687 @default.
• W2098486516 cites W2183638947 @default.
• W2098486516 cites W2241079867 @default.
• W2098486516 cites W3009041318 @default.
• W2098486516 cites W93164460 @default.
• W2098486516 doi "https://doi.org/10.1111/j.1464-410x.2010.09829.x" @default.
• W2098486516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21078050" @default.
• W2098486516 hasPublicationYear "2010" @default.
• W2098486516 type Work @default.
• W2098486516 sameAs 2098486516 @default.
• W2098486516 citedByCount "20" @default.
• W2098486516 countsByYear W20984865162012 @default.
• W2098486516 countsByYear W20984865162013 @default.
• W2098486516 countsByYear W20984865162014 @default.
• W2098486516 countsByYear W20984865162015 @default.
• W2098486516 countsByYear W20984865162017 @default.
• W2098486516 countsByYear W20984865162018 @default.
• W2098486516 crossrefType "journal-article" @default.
• W2098486516 hasAuthorship W2098486516A5033091020 @default.
• W2098486516 hasAuthorship W2098486516A5049048398 @default.
• W2098486516 hasAuthorship W2098486516A5062519984 @default.
• W2098486516 hasAuthorship W2098486516A5074756323 @default.
• W2098486516 hasAuthorship W2098486516A5090509109 @default.
• W2098486516 hasConcept C121608353 @default.
• W2098486516 hasConcept C126322002 @default.
• W2098486516 hasConcept C143998085 @default.
• W2098486516 hasConcept C168563851 @default.
• W2098486516 hasConcept C177713679 @default.
• W2098486516 hasConcept C183713625 @default.
• W2098486516 hasConcept C185592680 @default.
• W2098486516 hasConcept C190283241 @default.
• W2098486516 hasConcept C2776694085 @default.
• W2098486516 hasConcept C2776820818 @default.
• W2098486516 hasConcept C2777472916 @default.
• W2098486516 hasConcept C2777802072 @default.
• W2098486516 hasConcept C2778019345 @default.
• W2098486516 hasConcept C2778439243 @default.
• W2098486516 hasConcept C2778695046 @default.

• next